Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/Ribavirin therapy in chronic hepatitis C patients

Journal of Gastroenterology

Volumn 49, Issue 1, 2014, Pages 126-137

  Murata, Kazumoto ^a   Sugiyama, Masaya ^a   Kimura, Tatsuji ^b   Yoshio, Sachiyo ^c   Kanto, Tatsuya ^c   Kirikae, Ikue ^a   Saito, Hiroaki ^a   Aoki, Yoshihiko ^a   Hiramine, Satoshi ^a   Matsui, Teppei ^a   Ito, Kiyoaki ^a   Korenaga, Masaaki ^a   Imamura, Masatoshi ^a   Masaki, Naohiko ^a   Mizokami, Masashi ^a  

^a 1 7 1 Kohnodai   (Japan)

^b Institute of Immunology Co Ltd   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis C; IFN 3; IL28B; Peg IFN RBV

Indexed keywords

AGED; AMINOQUINOLINES; ANTIVIRAL AGENTS; CELLS, CULTURED; DENDRITIC CELLS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RIBAVIRIN; RNA, MESSENGER; TOLL-LIKE RECEPTOR 7; TREATMENT OUTCOME;

EID: 84895073593     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0814-1     Document Type: Article

References (41)

1. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105-9.
2. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
3. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100-4.
4. Ng HH, Bird A. DNA methylation and chromatin modification. Curr Opin Genet Dev. 1999;9:158-63.
5. Kotenko SV, Gallagher G, Baurin VV, et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4:69-77.
6. Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4:63-8.
7. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C replication. J Virol. 2005;79:3851-4.
8. Ank N, Iversen MB, Bartholdy C, et al. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol. 2008;180:2474-85.
9. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38:645-52.
10. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C. Nature. 2009;46:798-802.
11. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139:120-9.
12. Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann NY Acad Sci. 2008;1143:1-20.
13. Loo YM, Owen DM, Li K, et al. Viral and therapeutic control of IFN-β promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci USA. 2006;103:6001-6.
14. Meylan E, Curran J, Hofmann K, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature. 2005;437:1167-72.
15. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675-80.
16. Siren J, Pirhonen J, Julkunen I, et al. IFN-α regulates TLR-dependent gene expression of IFN-α, IFN-β, IL-28, and IL-29. J Immunol. 2005;174:1932-7.
17. Ito K, Higami K, Masaki N, et al. The rs8099917 polymorphism, determined by a suitable genotyping method, is a better predictor for response to pegylated interferon-α/ribavirin therapy in Japanese patients than other SNPs associated with IL28B. J Clin Microbiol. 2011;49:1853-60.
18. Sugiyama M, Kimura T, Naito S, et al. Development of interferon lambda 3 specific quantification assay for its mRNA and serum/plasma specimens. Hepatol Res. 2012;42:1089-99.
19. Takahashi H, Ono N, Eguchi Y, et al. Evaluation of acoustic radiation force impulse elastography for fibrosis staging of chronic liver disease: a pilot study. Liver Int. 2010;30:538-45.
20. + DCs are major producers of IFN-λ in response to poly IC. J Exp Med. 2009;207:2703-17.
21. Dzionek A, Fuchs A, Schmidt P, et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol. 2000;165:6037-46.
22. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061-9.
23. Saito H, Ito K, Sugiyama M, et al. Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral clearance to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients. Hepatol Res. 2012;42:958-65.
24. Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010;52:421-9.
25. Thomas E, Gonzalez VD, Li Q, et al. HCV infection induces a unique hepatic innate responses associated with robust production of type III interferons. Gastroenterology. 2012;142:978-88.
26. Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients and donors correlate with response to Peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology. 2010;139:1577-85.
27. Honda M, Sakai A, Yamashita T, et al. Hepatic interferon-stimulated genes expression is associated with genetic variation in interleukin 28B and the outcome of interferon therapy for chronic hepatitis C. Gastroenterology. 2010;139:499-509.
28. Yin Z, Dai J, Deng J, et al. Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol. 2012;189:2735-45.
29. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303:1526-9.
30. Diebold SS, Kaisho T, Hemmi H, et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303:1529-31.
31. Lund JM, Alexopoulou L, Sato A, et al. Recognition of single-stranded RNA viruses by toll-like receptor 7. Proc Natl Acad Sci USA. 2004;101:5598-603.
32. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196-200.
33. Gorden KB, Gorski KS, Gibson SJ, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol. 2005;174:1259-68.
34. Chang S, Kodys K, Szabo G. Impaired expression and function of toll-like receptor 7 in hepatitis C virus infection in human hepatoma cells. Hepatology. 2010;51:35-42.
35. Dellgren C, Gad HH, Hamming OJ, et al. Human interferon-λ3 is a potent member of the type III interferon family. Genes Immun. 2009;10:125-31.
36. Osterlund PI, Pietilä TE, Veckman V, et al. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-λ) genes. J Immunol. 2007;179:3434-42.
37. O'Brien TR. Interferon-alfa, interferon-lambda and hepatitis C. Nat Genet. 2009;41:1048-50.
38. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958-65.
39. Picard C, Puel A, Bonnet M, et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science. 2003;299:2076-9.
40. Urban TJ, Thompson AJ, Bradrick SS, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology. 2010;52:1888-96.
41. Sugiyama M, Tanaka Y, Wakita T, et al. Genetic variation of the IL28B promoter affecting gene expression. PLoS ONE. 2011;6:e26620.